Combination products present a uniquely complex path from late-stage clinical development to commercial launch due to their need to comply with the corresponding drug, biologic, and medical device regulatory frameworks. The designation of Primary Mode of Action (PMOA) determines the lead regulatory authority and submission pathway, but it does not eliminate the obligation to address requirements from the non-lead constituent. As a result, organizations must manage parallel regulatory expectations spanning formulation stability, container closure integrity, device usability, labeling controls, and post-market compliance. This dual oversight significantly increases development, validation, and launch complexity.
The final stages of clinical development often focus on confirming clinical safety and efficacy, but for combination products, another layer of complexity arises: ensuring that packaging, labeling, and stability are optimized for commercial scale. Small adjustments that may seem benign during clinical trials can have far-reaching consequences when scaled up for commercial production, impacting stability profiles, shelf life, verification and validation (V&V) status, and even regulatory submissions.
For combination products, successful commercialization depends on early recognition of these intersecting regulatory and technical demands, and on disciplined planning to manage the downstream impacts on stability programs, verification and validation activities, and time-to-market.
The Transitional Gap Between Clinical and Commercial Stages
In clinical development, the primary objective is patient safety, usability, and efficacy under controlled conditions. By contrast, commercialization demands consistent performance, manufacturability, and long-term stability across large-scale production and distribution networks; all while maintaining the usability considerations of the product.
This creates a translational gap; where materials, components, or processes used for clinical supply must evolve to meet commercial and regulatory expectations. For combination products, this gap is more pronounced because both pharmaceutical and device design controls come into play.
Key challenges often include:
- Scaling manufacturing from small-batch to high-volume production while maintaining product integrity.
- Transitioning from investigational to market-ready labeling, including safety updates, device instructions, and serialization requirements.
- Adjusting packaging for long-term storage, transportation considerations, or regional market requirements.
- Ensuring that any design or packaging modifications do not invalidate prior verification and validation results.
Stability Concerns: Clinical Development vs. Commercial Shelf Life
a. Clinical-stage stability testing
During clinical trials, stability studies are typically accelerated and abbreviated, designed to support investigational use. These studies aim to confirm that the product remains safe and effective over the duration of the trial, under storage and shipping conditions relevant to the investigational environment.
At this stage:
- Stability protocols are often tailored for short-term needs (e.g., 6–12 months).
- Environmental stress testing may be limited.
- Packaging configurations may not reflect the final commercial presentation (e.g., bulk vials instead of final-dose pens or prefilled syringes).
- The device component, if used, may be sourced from a prototype or limited-scope supplier.
- Clinical stability programs are often risk-based and justified through protocol rationale.
This approach is sufficient for clinical purposes, but it does not provide the comprehensive stability data required for regulatory approval and commercial release. Accelerated or abbreviated stability studies are acceptable for IND or in general Clinical Trial Application (CTA) submissions but not sufficient for marketing applications.
b. Commercial-stage stability expectations
When transitioning to commercialization, stability programs must evolve substantially. Regulators require full ICH-compliant stability data demonstrating long-term product quality and performance across defined environmental conditions and shelf-life periods. For combination products, both the drug formulation and the device/packaging system contribute to the overall stability profile.
Typical commercial-stage stability requirements include:
- ICH Q1A (R2) compliant long-term (real-time), accelerated, and stress testing.
- Multiple lots representative of full-scale commercial production.
- Evaluation of product–package and product–device interactions.
- Data supporting label claims for shelf life (often 18–36 months).
- Studies assessing the effects of temperature excursions and distribution stress.
A major challenge arises when the final packaging or device configuration differs from the one used in clinical trials. Any such change can introduce new stability variables, requiring partial or full re-validation of the stability program.
Stability must demonstrate the performance of the integrated drug-device system. Real-time data is commonly paired with accelerated aging data and post-approval commitments to address long-term data that is still accruing at the time of submission.
How Packaging Decisions Influence Stability
The packaging of a combination product is a functional component that can influence product performance, safety, and shelf life. This is particularly true when packaging materials interact physically or chemically with the drug component, or when the packaging also serves as the delivery device (e.g., prefilled syringes, autoinjectors, inhalers).
a. Packaging differences between clinical and commercial stages
During clinical development, simplicity and flexibility are prioritized. Packaging often focuses on:
- Small-batch packaging configurations.
- Manual or semi-automated assembly.
- Non-branded or plain packaging to facilitate blinding.
- Minimal labeling and instructions.
However, when moving toward commercialization, packaging must meet market, regulatory, and operational requirements, such as:
- Branding, serialization, and anti-counterfeiting features.
- Multilingual labeling and patient information leaflets.
- Child-resistant or tamper-evident features.
- Compatibility with high-speed automated packaging lines.
- Regulatory compliance across multiple regions (FDA, EMA, PMDA, etc.).
Each of these changes can impact stability, mechanical stress tolerance, or moisture/oxygen ingress even if the core drug-device configuration remains unchanged.
b. Stability concerns from packaging modifications
A few examples illustrate the interconnectedness of packaging and stability:
- Material permeability: A switch from a glass vial to a polymer prefilled syringe could alter moisture or oxygen transmission rates, affecting drug stability.
- Lubricants and coatings: Silicone oil used in syringes can interact with biologics, leading to aggregation or particle formation over time.
- Label adhesives: Certain label materials and inks can leach or migrate, particularly under accelerated conditions, potentially affecting stability.
- Light exposure: Moving from opaque to transparent packaging for aesthetic or marketing reasons may introduce photostability risks.
- Secondary packaging: Carton design, tray layout, and secondary sealing may affect product protection during storage/shipment or validated sterilization configurations.
Such considerations require bridging studies or comparability protocols to demonstrate that the new packaging does not negatively affect product performance or shelf life.
Labeling and Artwork Evolution: From Clinical Simplicity to Commercial Complexity
Labeling may seem administrative, but it’s one of the most regulated and technically complex aspects of commercialization. For combination products, labeling includes not just text and artwork but also instructions for use (IFU), and device markings.
a. Clinical labeling
Clinical labeling is typically:
- Minimal and monochrome.
- Focused on investigational information (“For Investigational Use Only”).
- Provided in one language or region-specific language.
- Without serialization or 2D barcodes.
- Controlled under investigational labeling SOPs.
b. Commercial labeling requirements
Commercial labeling, however, must satisfy both regulatory compliance and market needs, including:
- Final drug name, dosage, and strength.
- Legally approved IFUs and device graphics.
- Multiple language requirements for global distribution.
- Anti-tampering and serialization features under the Drug Supply Chain Security Act (DSCSA) or EU FMD.
- Harmonized packaging hierarchy (unit of use, intermediate, and shipper labels).
- Consistent brand identity and patient usability design.
Each of these elements requires new verification and validation activities, particularly for labeling software, artwork management systems, and automated vision inspection systems.
Labeling changes introduced after clinical development should be evaluated using a risk-based approach aligned with ISO 14971, recognizing labeling as a critical risk control for combination products. Instructions for use, warnings, symbols, and device markings are often key mitigations for use-related hazards identified during risk analysis. When labeling content, layout, language, or presentation is modified for commercialization, the effectiveness of those risk controls may change. Under ISO 14971, any modification that could impact the user’s ability to correctly understand or execute a critical task must be assessed for residual risk. As a result, labeling changes made after clinical trials may necessitate additional human factors validation or focused usability testing to demonstrate that the updated labeling continues to adequately mitigate use-related risks and does not introduce new hazards. Failure to apply this risk-based evaluation can lead to regulatory questions, delayed approvals, or post-market safety concerns.
Impact on Verification and Validation (V&V)
Transitioning to commercial packaging and labeling introduces numerous verification and validation implications. Many organizations underestimate how even small changes; a new adhesive, carton materials, or label layout, can trigger re-validation requirements.
a. When changes trigger re-validation
Changes between the clinical and commercial configurations often require:
- Design verification updates to confirm that new components meet user needs and specifications.
- Process validation updates to ensure manufacturing reproducibility at scale.
- Packaging validation to verify seal integrity, shipping robustness, and device fit.
- Labeling system validation to ensure data accuracy and traceability.
- Software validation for serialization, artwork management, or device firmware (if applicable).
For example, moving from a manually labeled clinical configuration to an automated labeling line introduces new vision systems and data-handling software, all of which must be validated under FDA 21 CFR Part 11 and ISO 13485 standards.
b. Risk-based approach to re-validation
Not every modification requires full re-validation. A risk-based approach aligned with ISO 14971 can help determine the extent of testing and documentation needed. This typically involves:
- Conducting a comparability assessment or gap analysis between the clinical and commercial configurations.
- Evaluating potential impact to critical quality attributes (CQAs) and critical process parameters (CPPs).
- Documenting rationale for partial verification or justification for no-impact changes.
- Implementing bridging studies for stability or functionality where applicable.
Such an approach helps maintain compliance while managing timelines and resources effectively.
Cross-functional Integration: The Key to Success
The transition from late-stage clinical to commercial readiness cannot occur in silos. Success requires tight cross-functional collaboration among pharmaceutical scientists, device engineers, quality assurance, regulatory affairs, and commercial packaging teams.
Best practices include:
- Early engagement of commercial packaging engineers during clinical design to anticipate scalability and stability impacts.
- Joint stability and packaging reviews to identify potential incompatibilities before submission.
- Parallel design control and process validation planning to align pharmaceutical and device requirements.
- Regulatory communication strategies (e.g., pre-submission meetings) to discuss bridging data, stability plans, and labeling readiness.
- Iterative usability studies that integrate commercial labeling and IFUs into late-stage human factors validation.
This proactive collaboration can mitigate late-stage rework, prevent costly delays, and accelerate regulatory approval.
Conclusion: Building a Bridge, Not a Leap
Successfully transitioning a combination product from late-stage clinical development to commercial launch requires deliberate alignment across stability, packaging, labeling, and validation. As outlined, clinical stability programs must mature into ICH-compliant strategies that support labeled shelf life, particularly when commercial packaging or delivery configurations differ from those used in trials. Likewise, commercialization-driven packaging and labeling changes; including serialization, finalized IFUs, and global artwork, must be evaluated using a risk-based framework to ensure they continue to mitigate use-related hazards and do not introduce new risks, often necessitating targeted human factors validation.
By proactively managing these interdependencies and applying disciplined, risk-based decision-making, organizations can bridge the clinical-to-commercial gap while strengthening submission readiness. Our focus is to help teams translate late-stage clinical programs into robust, well-defended NDA or BLA submissions, ensuring that stability, packaging, labeling, and verification strategies are fully aligned with regulatory expectations and positioned to support a successful review and launch.
At Ventura Solutions, we specialize in helping medical device and combination product companies navigate complex challenges throughout all stages of development. Whether you need end-to-end support with an integrated device team, quality or regulatory consulting, assistance with DHF remediation, additional staffing needs, employee training, or more; our team of experts are ready to help. Contact us today.
Interested in learning more about medical device and combination product development? Subscribe to our newsletter below for expert insights, the latest developments in the medical device and combination product space, and exciting career opportunities!
